462 related articles for article (PubMed ID: 19031955)
1. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
2. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
Turello R; Rentsch K; Di Paolo E; Popovic MB
Pediatr Blood Cancer; 2008 Jan; 50(1):154-6. PubMed ID: 17387702
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
4. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.
Schmeling H; Biber D; Heins S; Horneff G
J Rheumatol; 2005 Sep; 32(9):1832-6. PubMed ID: 16142884
[TBL] [Abstract][Full Text] [Related]
5. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
[TBL] [Abstract][Full Text] [Related]
6. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
[TBL] [Abstract][Full Text] [Related]
8. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
10. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
Gammon DC; Bhatt MS; Patel B; Anderson M; Van Horn A; Glantz MJ
J Oncol Pharm Pract; 2008 Sep; 14(3):153-6. PubMed ID: 18719070
[TBL] [Abstract][Full Text] [Related]
11. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
12. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
van Kooten Niekerk PB; Schmiegelow K; Schroeder H
Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
[TBL] [Abstract][Full Text] [Related]
13. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
Aplenc R; Thompson J; Han P; La M; Zhao H; Lange B; Rebbeck T
Cancer Res; 2005 Mar; 65(6):2482-7. PubMed ID: 15781665
[TBL] [Abstract][Full Text] [Related]
14. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
[TBL] [Abstract][Full Text] [Related]
16. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice.
Celtikci B; Leclerc D; Lawrance AK; Deng L; Friedman HC; Krupenko NI; Krupenko SA; Melnyk S; James SJ; Peterson AC; Rozen R
Pharmacogenet Genomics; 2008 Jul; 18(7):577-89. PubMed ID: 18551038
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.
Vagace JM; Caceres-Marzal C; Jimenez M; Casado MS; de Murillo SG; Gervasini G
Am J Hematol; 2011 Jan; 86(1):98-101. PubMed ID: 21064136
[TBL] [Abstract][Full Text] [Related]
19. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]